Researchers have reported notable advances in the war on cancer, but they cautioned that the disease continues to throw up daunting obstacles of cost and complexity. New data presented at a major cancer conference provided both practice-changing information on the use of current treatments and powerful evidence of the potential for targeted therapies, which attack cancer via genetic targets and other vulnerabilities. The latest advances, however, typically involve expensive drugs that will require difficult choices by doctors, patients, and insurers amid growing concern over healthcare costs, the Wall Street Journal reports.
